The Importance of Rare Disease Registries
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses the importance of rare disease registries.
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses the importance of rare disease registries.
Analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy was associated with favorable survival outcomes vs…
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality
The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.
Background Adoptive cell therapy, such as chimeric antigen receptor (CAR)-T cell therapy, has improved patient outcomes for hematological malignancies. Currently, four of the six FDA-approved…
Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.
A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.
Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.